AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Daratumumab (Primary) ; Elranatamab (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms MAGNETISMM-5
- Sponsors Pfizer
- 05 Jun 2024 Planned number of patients changed from 762 to 761.
- 05 Jun 2024 Planned End Date changed from 28 Sep 2026 to 31 May 2027.
- 05 Jun 2024 Planned primary completion date changed from 27 Dec 2024 to 1 Aug 2025.